Estrogen Receptor (ER) and Progesterone Receptor (PgR) Expression in Endometrial Cancer-An Immunohistochemical Assessment
View abstract on PubMed
Summary
This summary is machine-generated.Progesterone receptor (PgR) and estrogen receptor (ER) expression loss in endometrial cancer (EC) correlates with poor prognosis. Lower PgR levels are linked to high-grade EC, while ERb1 expression decreases in advanced stages.
Area Of Science
- Oncology
- Pathology
- Biochemistry
Background
- Endometrial cancer (EC) is a prevalent malignancy globally and in Poland.
- Risk factors include lifestyle, BMI, breast cancer therapies, and Lynch syndrome.
- Estrogen receptors (ERs) and progesterone receptors (PgR) are crucial in EC pathogenesis, with their loss indicating a poor prognosis.
Purpose Of The Study
- To objectively assess ER and PgR expression in endometrial cancer tissues.
- To correlate receptor expression levels with EC grade, stage, and histological type.
- To investigate the prognostic significance of ER and PgR expression in EC.
Main Methods
- Computer image analysis of tissue slides from 103 women with EC.
- Quantitative assessment of progesterone receptor (PgR) expression.
- Evaluation of estrogen receptor beta 1 (ERb1) expression in relation to disease stage.
Main Results
- Significantly lower PgR expression in high-grade (G3) EC compared to low-grade EC.
- PgR expression is higher in early FIGO stages and in endometrioid EC subtypes.
- ERb1 expression was found to be lower in stage IV EC compared to stage III EC.
Conclusions
- Reduced PgR expression is associated with aggressive endometrial cancer features (high grade, advanced stage).
- Loss of ER and PgR expression is a significant indicator of poor prognosis in endometrial cancer.
- Objective computer-aided analysis enhances the reliability of assessing prognostic biomarkers in EC.

